India markets closed
  • BSE SENSEX

    40,544.37
    +112.77 (+0.28%)
     
  • Nifty 50

    11,896.80
    +23.75 (+0.20%)
     
  • Dow

    28,195.42
    -410.89 (-1.44%)
     
  • Nasdaq

    11,478.88
    -192.67 (-1.65%)
     
  • BTC-INR

    873,535.06
    +61,980.50 (+7.64%)
     
  • CMC Crypto 200

    240.62
    +6.95 (+2.98%)
     
  • Hang Seng

    24,569.54
    +27.28 (+0.11%)
     
  • Nikkei

    23,567.04
    -104.09 (-0.44%)
     
  • EUR/INR

    86.8183
    +0.4807 (+0.56%)
     
  • GBP/INR

    95.1868
    +0.2683 (+0.28%)
     
  • AED/INR

    19.9580
    +0.0320 (+0.16%)
     
  • INR/JPY

    1.4341
    -0.0005 (-0.03%)
     
  • SGD/INR

    54.1520
    +0.1360 (+0.25%)
     

GV Prasad of Dr Reddy's Laboratories on the partnership with Russian Direct Investment Fund & more

In an exclusive conversation with ET NOW, GV Prasad, Co-chairman & MD, Dr. Reddy's Laboratories speaks on Remlivid settlement, DRL-RDIF partnership, Sputnik vaccine tie-up and future acquisition plans and a lot more. Revlimid is an important drug settlement for the company, and it will be a significant product for DRL says Dr GV Prasad.

He remains confident that India is a dominant sector in the generics market and the healthcare industry will favour generics going forward as the government has recognised Pharma sector's importance after the COVID crisis. Speaking on growth, the DRL leader says they are aiming to enter new segments in Russia & DRL is responsible for Indian trials of Sputnik-V vaccine, the company is always looking for acquisitions in key markets like India, while the company is not overly dependent on China. He sees a dramatic change in the product mix in 3-5 years.